

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 2

In the Claims

Please cancel claims 125, 129-131, 134-151, 154 and 158-166 without disclaimer or prejudice to applicants' rights to pursue the subject matter of these claims in this or another application.

Please amend claims 123, 133, 152 and 157 in the subject application as set forth below in accordance with 37 C.F.R. §1.121 as amended by 68 Fed. Reg. 38611 (June 30, 2003).

1-122. (Canceled)

123. (currently amended) A method of treating a mammal afflicted with ~~an autoimmune disease~~ multiple sclerosis comprising administering to the mammal a single purified polypeptide, wherein the purified polypeptide having the comprises consecutive amino acids having an amino acid sequence set forth in any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides in an amount effective to treat the mammal.

124. (previously presented) The method of claim 123 wherein the purified polypeptide consists entirely of L-amino acids.

125. (Canceled)

126. (Canceled)

127. (previously presented) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 2.

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 3

128. (Canceled)

129. (Canceled)

130. (Canceled)

131. (Canceled)

132. (previously presented) The method of claim 123, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 7.

133. (currently amended) A method of treating a mammal afflicted with ~~an autoimmune disease~~ multiple sclerosis comprising administering to the mammal a pharmaceutical composition ~~consisting essentially of a~~ comprising a single purified polypeptide, wherein the purified polypeptide having the comprises consecutive amino acids having an amino acid sequence set forth in any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides, in an amount effective to treat the mammal and a pharmaceutically acceptable carrier.

134-151. (Canceled)

152. (currently amended) A method of delaying the onset of an ~~autoimmune disease~~ multiple sclerosis in a mammal comprising administering to the mammal a single purified polypeptide, wherein the purified polypeptide having the comprises consecutive amino acids having an amino acid sequence set forth in any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 4

polypeptides, in an amount effective to delay the onset of multiple sclerosis in the mammal.

153. (previously presented) The method of claim 152, wherein, the purified polypeptide consists entirely of L-amino acids.

154. (Canceled)

155. (previously presented) The method of claim 152, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 2.

156. (previously presented) The method of claim 152, wherein the purified polypeptide has the amino acid sequence set forth in SEQ ID NO: 7.

157. (currently amended) A method of delaying the onset of an autoimmune disease multiple sclerosis in a mammal comprising administering to the mammal a pharmaceutical composition ~~consisting essentially of a~~ comprising a single purified polypeptide, wherein the purified polypeptide having the comprises consecutive amino acids having an amino acid sequence set forth in any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7, or a mixture of the purified polypeptides, in an amount effective to delay the onset of multiple sclerosis in the mammal and a pharmaceutically acceptable carrier.

158-166. (Canceled)